Abata Therapeutics

Treg Cell Therapies

Undisclosed programs RD diabetes (1), RD inclusion body myositis

Abata Therapeutics is understanding the biology of T cells to create therapies for autoimmune diseases. Regulatory T cells (Tregs) are a critical component of the immune system that act to suppress the immune response preventing autoimmunity. Abata is using this knowledge to engineer Tregs as targeted therapies that stop immune-mediated destruction of normal cells and restore homeostasis. Treg engineering involves expression of a T cell receptor that recognizes a tissue-restricted antigen, to selectively target the therapy to the site of disease for a robust response. In addition, engineered Tregs are optimized for durability allowing the effects of a single dose to last years. Abata has initial programs for multiple sclerosis and Type 1 diabetes.